Flower lose, a cell fitness marker, predicts COVID-19 prognosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Flower lose, a cell fitness marker, predicts COVID-19 prognosis
Forlagets udgivne version, 2,63 MB, PDF-dokument
Risk stratification of COVID-19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe-Lose, can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe-Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID-19 patients. We performed a post-mortem examination of infected lung tissue in deceased COVID-19 patients to determine hFwe-Lose’s biological role in acute lung injury. We then performed an observational study (n = 283) to evaluate whether hFwe-Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID-19 patients. In COVID-19 patients with acute lung injury, hFwe-Lose is highly expressed in the lower respiratory tract and is co-localized to areas of cell death. In patients presenting in the early phase of COVID-19 illness, hFwe-Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe-Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D-dimer, C-reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe-Lose, accurately predicts outcomes in COVID-19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID-19 pandemic.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | e13714 |
| Tidsskrift | EMBO Molecular Medicine |
| Vol/bind | 13 |
| Udgave nummer | 11 |
| Antal sider | 17 |
| ISSN | 1757-4676 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
This study was supported by Swiss Cancer League, Seeds of Science, UAMS, SNSF, Fundação para a Ciência e a Tecnologia, Fundamental Mandates (Stichting tegen Kanker—Fondation contre le Cancer) to R.G.; ERC, SNSF, Josef Steiner Cancer Research Foundation, Swiss Cancer League, and Champalimaud Foundation to E. Mo.; Novo Nordisk Foundation [NNF17CC0027852] and Lundbeck Foundation [R313–2019–421] to K.J.W.; La Caixa Funding LCF/BQ/PR20/11770006 to E. Ma.; FIS (Ministry of Health), Madrid, Spain, Grant PI17/01981 to A.L‐.B.;. DFG Clinical Research Unit KFO 309, and the German Center for Lung Research (DZL), DFG Collaborative Research Center SFB1021 to J.W.; Deutsche Forschungsgemeinschaft (DFG) Clinical Research Group KFO309 TP08, the DFG‐funded Excellence Cluster Cardio‐Pulmonary Institute (CPI), and the German Center for Lung Research (DZL) to T.B.; Botnar Research Centre for Child Health (BRCCH) (FTC‐2020‐10) and SNSF to A.T., T.M., M.M. & J.D.H.; Support from the Thelma Newmeyer Corman Chair in Cancer Research, the VCU Commercialization Fund and NIH/NCI R01 CA259599 to P.B.F.; Fundação para a Ciência e a Tecnologia Grant 2020.05319.BD to A.M.P.; Fundação para a Ciência e a Tecnologia Grant SFRH/BD/139138/2018 to R.C.D.; Fundação para a Ciência e a Tecnologia and PGCD—Programa de Pós‐Graduação Ciência para o Desenvolvimento SFRH / BD/135367/2017 to D.C.; Tumor Microenvironment (TME) CoBRE Grant (NIH/NIGMS P20GM121322), West Virginia IDeA‐CTR (NIH/NIGMS 2U54 GM104942‐03), National Science Foundation (NSF/1920920, NSF/1761792), West Virginia IDeA Network of Biomedical Research Excellence (WV‐INBRE) (NIH/NIGMS P20GM103434) to I.M.; and Adelson Medical Research Foundation, NIH P50 SPORE CA228991, Honorable Tina Brozman Foundation for Ovarian Cancer Research to R.D. The author(s) thank the Translational Science Biocore (TSB) BioBank of the University of Wisconsin Carbone Cancer Center and the clinical laboratory at the University of Wisconsin Hospitals for providing specimens and associated clinical data used in this research. The Translational Science Biocore (TSB) BioBank of the University of Wisconsin Carbone Cancer Center and the clinical laboratory at the University of Wisconsin Hospitals are supported by P30 CA014520 and received dedicated support for COVID‐associated work from the University of Wisconsin School of Medicine and Public Health. We thank Taylor M. Parker for thorough reading of the manuscript. We thank Dr. Timothy Eubank at WVU for his kind support with the organization and purchase of RNA extraction kits (West Virginia Clinical and Translational Science Institute (WVCTSI) Grant GM104942). We thank Aenya Gogna for supporting the entire process involving research activity and writing of the manuscript. We thank Sunita Gogna and Keshav Chandra Gogna who suffered major COVID‐19 disease, and they continuously discussed their disease progression over a period of 4 months. This helped our team in deeper understanding of the subject. We sincerely thank Mr. Luís Nunes from the Ritz Carlton, Penha Longa Resort Estrada da Lagoa Azul, Linhó, Sintra, Portugal. The Penha Longa management regularly arranged for the meeting space and facilitated important discussions between collaborators during the time of total shutdown due to the declared national emergency in Portugal. Grant
Publisher Copyright:
© 2021 The Authors. Published under the terms of the CC BY 4.0 license
ID: 282471969